Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126925051 | 12692505 | 1 | I | 20160815 | 20160829 | 20160829 | EXP | US-CIPLA LTD.-2016US17580 | CIPLA | BOHORQUEZ HE, COHEN AJ, GIRGRAH N, BRUCE DS, CARMODY IC, JOSHI S ET AL.,. LIVER TRANSPLANTATION IN HEPATITIS B CORE-NEGATIVE RECIPIENTS USING LIVERS FROM HEPATITIS B CORE-POSITIVE DONORS: A 13-YEAR EXPERIENCE. LIVER TRANSPLANTATION. 2013;19:611 TO 618 | 0.00 | Y | 0.00000 | 20160829 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126925051 | 12692505 | 1 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | 150 MG, QD | U | U | 0 | 150 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126925051 | 12692505 | 1 | Antiviral prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126925051 | 12692505 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126925051 | 12692505 | Drug ineffective | |
| 126925051 | 12692505 | Drug resistance | |
| 126925051 | 12692505 | Hepatic enzyme increased | |
| 126925051 | 12692505 | Hepatitis B |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |